Table 5.

Clinically Significant Drug Interactions with Common LAIs

LAI	Interacting drug or class	Potential effect	Management recommendation
All LAIs	QT interval-prolonging drugs	Increased risk of QTc prolongation	Use with caution, monitor ECG
	CNS depressants (eg, alcohol)	Increased risk of sedation and respiratory depression	Avoid concomitant use
Aripiprazole (Abilify Asimtufii)	Strong inhibitors of CYP2D6 and CYP3A4	Increased aripiprazole exposure	Avoid use
Aripiprazole (Abilify Maintena)	Carbamazepine	Decreased aripiprazole concentrations	Consider higher dose of aripiprazole
	Strong CYP3A4 Inhibitors (eg, ketoconazole)	Increased risk of aripiprazole overexposure	Reduce aripiprazole dose
	Strong CYP3A4 Inducers (eg, rifampin)	Decreased aripiprazole concentrations	Avoid use
Olanzapine (Zyprexa Relprevv)	Fluvoxamine	Increased olanzapine concentrations	Consider lower dose of olanzapine
	Diazepam	Potentiated orthostatic hypotension	Use with caution, monitor blood pressure
Paliperidone Palmitate (Invega Sustenna)	Carbamazepine	Decreased paliperidone concentrations	Consider managing with oral paliperidone
	Strong CYP3A4/P-gp Inducers (eg, rifampin)	Decreased paliperidone exposure	Consider managing with oral paliperidone
Risperidone (Risperdal Consta)	Fluoxetine/Paroxetine	Increased risperidone concentrations	Consider lower dose of risperidone
	Carbamazepine	Decreased risperidone plasma concentration	May require higher dose of risperidone